Abstract
The sulfonamides constitute an important class of drugs, which display a variety of activities including antibacterial, anticarbonic anhydrase, diuretic, hypoglycemic and antithyroid effectiveness. A number of sulfonamides have been reported to be potent anticancer agents, which interact with a wide range of different cellular targets. Among these interesting sulfonamides, the diaryl or heterocyclic sulfonamides have recently emerged as an important class of antimitotic agents against different types of cancer, including multidrug resistant tumors. This review summarizes the recent advances of the diaryl or heterocyclic sulfonamides as novel antimitotic agents.
Keywords: Antimitotic Agents, Heterocyclic Sulfonamides, anticarbonic anhydrase, hypoglycemic, potent anticancer agents, tumor cell, structure-activity relationships (SAR)
Anti-Cancer Agents in Medicinal Chemistry
Title: Novel Diaryl or Heterocyclic Sulfonamides as Antimitotic Agents
Volume: 8 Issue: 7
Author(s): Laixing Hu, Zhuo-rong Li, Jian-dong Jiang and David W. Boykin
Affiliation:
Keywords: Antimitotic Agents, Heterocyclic Sulfonamides, anticarbonic anhydrase, hypoglycemic, potent anticancer agents, tumor cell, structure-activity relationships (SAR)
Abstract: The sulfonamides constitute an important class of drugs, which display a variety of activities including antibacterial, anticarbonic anhydrase, diuretic, hypoglycemic and antithyroid effectiveness. A number of sulfonamides have been reported to be potent anticancer agents, which interact with a wide range of different cellular targets. Among these interesting sulfonamides, the diaryl or heterocyclic sulfonamides have recently emerged as an important class of antimitotic agents against different types of cancer, including multidrug resistant tumors. This review summarizes the recent advances of the diaryl or heterocyclic sulfonamides as novel antimitotic agents.
Export Options
About this article
Cite this article as:
Hu Laixing, Li Zhuo-rong, Jiang Jian-dong and Boykin W. David, Novel Diaryl or Heterocyclic Sulfonamides as Antimitotic Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (7) . https://dx.doi.org/10.2174/187152008785914806
DOI https://dx.doi.org/10.2174/187152008785914806 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Auther index to Volume 2
Current Cancer Therapy Reviews Recombination Functions of Replication Protein A
Current Organic Chemistry MRI of the Small and Large Bowel
Current Medical Imaging Targeting the EGF/HER Ligand-Receptor System in Cancer
Current Pharmaceutical Design Acknowledgement to Reviewers
Recent Patents on Anti-Cancer Drug Discovery Treatment of Squamous Cell Carcinoma of the Head and Neck in the Metastatic and Refractory Settings: Advances in Chemotherapy and the Emergence of Small Molecule Epidermal Growth Factor Receptor Kinase Inhibitors
Current Cancer Drug Targets MUC1 is a Promising Therapeutic Target for Prostate Cancer Therapy
Current Cancer Drug Targets Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Physiological Functions of Heat Shock Proteins
Current Protein & Peptide Science Arylurea Derivatives: A Class of Potential Cancer Targeting Agents
Current Topics in Medicinal Chemistry Chemistry and Pharmacology of Bioactive Molecule -Coenzyme Q10: A Brief Note
Current Bioactive Compounds Carbon Nanohybrids as Electro-Responsive Drug Delivery Systems
Mini-Reviews in Medicinal Chemistry SUBJECT INDEX TO VOLUME 1
Current Drug Targets Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer
Current Medical Imaging Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy MicroRNAs in Cancer Gene Therapy: Another Look
Current Cancer Therapy Reviews Editorial (Thematic Issue: Biosafety of Viral Vectors Commonly Used in Gene Therapy and Vaccination)
Current Gene Therapy Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer
Reviews on Recent Clinical Trials Design of Ru-arene Complexes for Antitumor Drugs
Mini-Reviews in Medicinal Chemistry The Cholinergic Potential, the Vagus Nerve and Challenges in Treatment of Traumatic Brain Injury
Current Pharmaceutical Design